Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 16, 2023

BUY
$0.3 - $0.58 $23,806 - $46,025
79,355 Added 214.37%
116,372 $37,000
Q4 2022

Feb 14, 2023

BUY
$0.37 - $8.65 $744 - $17,403
2,012 Added 5.75%
37,017 $14,000
Q3 2022

Nov 14, 2022

BUY
$0.49 - $7.65 $1,430 - $22,338
2,920 Added 9.1%
35,005 $16,000
Q2 2022

Aug 15, 2022

BUY
$0.73 - $1.34 $1,595 - $2,929
2,186 Added 7.31%
32,085 $26,000
Q1 2022

May 16, 2022

SELL
$0.89 - $1.85 $120,219 - $249,894
-135,078 Reduced 81.88%
29,899 $41,000
Q4 2021

Feb 14, 2022

BUY
$0.99 - $1.2 $124,027 - $150,336
125,280 Added 315.59%
164,977 $163,000
Q3 2021

Nov 15, 2021

SELL
$1.08 - $1.49 $112,342 - $154,991
-104,021 Reduced 72.38%
39,697 $43,000
Q1 2021

May 17, 2021

BUY
$1.38 - $2.28 $73,939 - $122,160
53,579 Added 59.44%
143,718 $217,000
Q4 2020

Feb 16, 2021

BUY
$1.2 - $1.69 $52,503 - $73,942
43,753 Added 94.32%
90,139 $123,000
Q2 2020

Aug 14, 2020

BUY
$0.42 - $1.26 $14,836 - $44,509
35,325 Added 319.37%
46,386 $58,000
Q1 2020

May 15, 2020

BUY
$0.32 - $0.77 $3,539 - $8,516
11,061 New
11,061 $5,000
Q4 2019

Feb 14, 2020

SELL
$0.32 - $3.15 $12,662 - $124,642
-39,569 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$1.79 - $3.33 $30,988 - $57,648
17,312 Added 77.78%
39,569 $111,000
Q2 2019

Aug 16, 2019

BUY
$1.43 - $2.32 $150 - $243
105 Added 0.47%
22,257 $43,000
Q2 2019

Aug 14, 2019

SELL
$1.43 - $2.32 $18,371 - $29,805
-12,847 Reduced 36.71%
22,152 $43,000
Q1 2019

May 15, 2019

BUY
$1.46 - $2.33 $51,098 - $81,547
34,999 New
34,999 $81,000
Q4 2018

Feb 14, 2019

SELL
$1.07 - $1.63 $57,335 - $87,343
-53,585 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$1.31 - $1.63 $37,756 - $46,979
28,822 Added 116.39%
53,585 $74,000
Q2 2018

Aug 14, 2018

BUY
$1.06 - $1.78 $26,248 - $44,078
24,763 New
24,763 $32,000

About Lipocine Inc.


  • Ticker LPCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,510,800
  • Market Cap $431M
  • Description
  • Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...
More about LPCN
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.